Dr Reddy’s Q4 FY25 results: profit up 22%, dividend

May 12 earnings calendar: key names to watch

A fresh set of companies is scheduled to declare January to March quarter results on Tuesday, May 12. The list spans utilities, pharma, electronics manufacturing services, paints, and textiles. Large and actively tracked names on the list include Tata Power, Dr Reddy’s Laboratories, Torrent Power, Dixon Technologies, Max Financial Services, and Berger Paints India. KPR Mill and Neuland Laboratories are also part of the scheduled announcements. The broader list referenced also includes Pfizer, Sagility, MTAR Technologies, and Ventive Hospitality.

Where Dr Reddy’s fits in the results flow

While May 12 is crowded, Dr Reddy’s financials are already in focus after the company announced audited Q4 FY25 and FY25 results for the year ended March 31, 2025. Separately, the data provided also mentions an “upcoming earnings date” of January 21, 2026 for Dr Reddy’s Laboratories Ltd. This creates two different reference points readers should keep distinct: the already-reported Q4 FY25 numbers, and the separately listed upcoming earnings date. For investors, the immediate takeaway is that Dr Reddy’s latest reported quarter showed strong year-on-year growth in revenue and profit.

Q4 FY25 headline numbers: revenue, profit, EBITDA

Dr Reddy’s reported consolidated revenue from operations of ₹8,506 crore in Q4 FY25, up 20% year-on-year from ₹7,083 crore. Profit after tax (PAT) attributable to equity holders came in at ₹1,593.9 crore, a 22% year-on-year increase from ₹1,307 crore. EBITDA for the quarter was reported at ₹2,474.9 crore, with EBITDA margin cited at about 29.1% of revenues in the audited results summary. Diluted EPS for the quarter was ₹19.11 (basic EPS ₹19.13 was also reported). The company also highlighted that it delivered its “highest ever quarterly revenues & profits” in Q4.

Full-year FY25 performance and balance sheet position

For FY25, Dr Reddy’s reported record annual revenue of ₹32,554 crore, reflecting 17% year-on-year growth. FY25 profit was reported at ₹5,654.4 crore, up marginally from ₹5,568.4 crore in FY24. The company’s audited results commentary also pointed to a strong balance sheet, with a net cash surplus of ₹2,454 crore. R&D spending for FY25 was reported at ₹2,738 crore, or 8.4% of revenue, supporting work across biosimilars, complex generics, and oncology assets. Gross margin for Q4 FY25 was reported at 55.6%, with FY25 gross margin at 58.5%.

Segment and geography snapshot: what drove Q4 growth

The global generics business remained central to the quarter, with Q4 revenue for the global generics segment reported at ₹7,540 crore, up 23% year-on-year. North America revenue in Q4 FY25 was cited at ₹3,559 crore, up 9% year-on-year and 5% sequentially. Europe revenue surged 145% year-on-year to about ₹1,280 crore, with the commentary noting this included NRT sales, and that excluding NRT growth was 30%. India revenue in Q4 FY25 was reported at about ₹1,300 crore, up 16% year-on-year but down 3% quarter-on-quarter. Emerging Markets revenue was cited at about ₹1,400 crore, up 16% year-on-year, and PSAI revenue was reported at ₹960 crore, up 16% year-on-year.

NRT integration and other operating levers

Dr Reddy’s highlighted the successful integration of its acquired Nicotine Replacement Therapy (NRT) business, and noted the nicotine portfolio supported growth in global generics. It also referenced partnerships for biosimilars and recognitions linked to sustainability efforts. The audited results note that profit before tax includes contributions from the recently acquired NRT business, with ₹88.8 crore in Q4 and ₹101.1 crore in FY25 attributed to it. On costs, the company reported Q4 SG&A expenses of ₹2,405.5 crore and Q4 R&D expenses of ₹725.8 crore.

Pipeline and FY26 actions mentioned by the company

The company outlined product launch plans for the US market. It expects to launch Rituximab in the US in FY26 and plans to introduce 18 to 20 new products in North America during the same period. It also stated it does not currently plan to set up a manufacturing unit in the US. Separately, it said it is assessing the impact of proposed tariffs with customers. These points matter because they connect the quarter’s performance with near-term execution items the market often tracks.

Dividend announcement and shareholder payout

Alongside the results, the board of directors recommended a final dividend of ₹8 per equity share (face value ₹1 each), subject to shareholder approval. For investors focused on capital returns, the announcement provides a clear data point tied to the FY25 outcome. The final decision will depend on the shareholder process as stated.

Market reaction: stock move reported around results

The stock’s reaction was reported in different ways across sources cited in the provided text. One report said shares of Dr Reddy’s closed 0.67% higher at about ₹1,156.4 on the BSE, even as the Sensex fell 1.1%. Another line stated the shares were down 0.67% at ₹1,156.40 at the close of trading on Friday, ahead of the earnings announcement. Taken together, the price points cited cluster around ₹1,156 to ₹1,158, but the direction is reported differently in the provided snippets.

Key financials table (Q4 FY25 and FY25)

Why this set of numbers matters amid a busy results week

Dr Reddy’s Q4 FY25 print is notable on two fronts visible in the provided data: a 20% year-on-year rise in quarterly revenue and a 22% rise in quarterly profit. The segment disclosures also show how the Europe line moved sharply year-on-year, explicitly tied to NRT, while India and Emerging Markets posted mid-teens year-on-year growth. The results also surface key operating metrics such as gross margin and R&D intensity, which are often used to compare pharma companies across cycles. Against that backdrop, May 12 results from other large names can shape broader market tone, but Dr Reddy’s detailed Q4 and FY numbers already provide a concrete reference point for pharma earnings momentum.

Conclusion

Dr Reddy’s reported Q4 FY25 revenue of ₹8,506 crore and PAT of ₹1,593.9 crore, alongside FY25 revenue of ₹32,554 crore and net cash surplus of ₹2,454 crore. The company also recommended a final dividend of ₹8 per share. Operationally, management highlighted NRT integration progress and outlined FY26 launch plans including Rituximab in the US and 18 to 20 new North America products. Investors will next map these updates against upcoming earnings dates and further disclosures as companies across sectors report results in the May 12 window.